Novella Clinical Bolsters Business Development with Three New Hires

Novella Clinical Bolsters Business Development with Three New Hires
RESEARCH TRIANGLE PARK, N.C., December 11, 2012 - Novella Clinical, a full service contract research organization (CRO), today announced an expanded business development team with the addition of three Directors of Client Service: Pamela Kennedy, RN; Fabio Mariano and Matthew O'Rourke.

Kennedy and Mariano, based in the U.S., specialize in medical device and diagnostics, while O'Rourke's expertise lies with small to mid-size biotechnology companies in Western Europe.

Pamela Kennedy
Kennedy joined Novella after leading business development efforts at a global CRO in the medical device and diagnostic space. With more than 30 years of experience in the medical device and pharmaceutical industries, she has held positions as an oncology nurse, clinical research associate, project manager, and clinical specialist with a medical device organization. Kennedy also previously led a team of clinical specialists at Cyberonics, the maker of a Class III implantable neuromodulation device, where she co-authored a successful regulatory submission for premarket approval.

Fabio Mariano
Mariano most recently served as an associate director of business development for an academic research organization where he specialized in developing collaborations with manufacturers of high-risk, minimally invasive medical devices. He began his career in a management consulting firm, advising senior management of life sciences organizations on growth strategy. Mariano has earned certifications from the Regulatory Affairs Professional Society after passing both the U.S. and European Union Regulatory Affairs Certification (RAC) exams, and holds an A.B. in Biochemical Sciences from Harvard University.

Matthew O'Rourke
O'Rourke, headquartered in Stevenage, England, is a seasoned business development professional with a career spanning nearly 10 years in a variety of biopharmaceutical services sales roles. Experienced in selling full service CRO capabilities, he also has expertise in clinical trial software. O'Rourke serves biotechnology and medical device clients in Western Europe.

"Novella's continued growth dictated the need for additional, highly qualified client service directors," said Nick Dyer, executive vice president, Novella Clinical. "Our new additions add value to sponsors from day one, understanding both the clinical and regulatory challenges facing industry today."

Novella's more than 800 global professionals provide a full range of clinical research outsourcing solutions as well as flexible resourcing models for oncology, medical device and biopharma companies. Currently supporting clients in 19 European countries, Novella continues to expand throughout the EU.

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Decentralized study company Medable has raised a large $91 million funding round as it continues to ramp up the deals in 2020.

Biotech IPOs are up over 40% year-to-date, but today’s markets have rewritten the rules for going public. Find out the new best practices for IPOs.

PRA Health has hired a former FDA clinical research lead to help run its decentralized study unit.